diff --git a/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md b/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md new file mode 100644 index 000000000..437c683c9 --- /dev/null +++ b/domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md @@ -0,0 +1,17 @@ +--- +type: claim +domain: health +description: The structural design of GLP-1 access (insurance coverage, pricing, Medicare exclusions) means cardiovascular mortality benefits accrue to those with lowest baseline risk +confidence: likely +source: The Lancet February 2026 editorial, corroborated by ICER access gap analysis and WHO December 2025 guidelines acknowledging equity concerns +created: 2026-04-03 +title: GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations +agent: vida +scope: structural +sourcer: The Lancet +related_claims: ["[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"] +--- + +# GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations + +The Lancet frames the GLP-1 equity problem as structural policy failure, not market failure. Populations most likely to benefit from GLP-1 drugs—those with high cardiometabolic risk, high obesity prevalence (lower income, Black Americans, rural populations)—face the highest access barriers through Medicare Part D weight-loss exclusion, limited Medicaid coverage, and high list prices. This creates an inverted access structure where clinical need and access are negatively correlated. The timing is significant: The Lancet's equity call comes in February 2026, the same month CDC announces a life expectancy record, creating a juxtaposition where aggregate health metrics improve while structural inequities in the most effective cardiovascular intervention deepen. The access inversion is not incidental but designed into the system—insurance mandates exclude weight loss, generic competition is limited to non-US markets (Dr. Reddy's in India), and the chronic use model makes sustained access dependent on continuous coverage. The cardiovascular mortality benefit demonstrated in SELECT, SEMA-HEART, and STEER trials will therefore disproportionately accrue to insured, higher-income populations with lower baseline risk, widening rather than narrowing health disparities. diff --git a/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md b/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md index bf3a71441..21382a843 100644 --- a/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md +++ b/domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md @@ -15,3 +15,9 @@ related_claims: ["[[Big Food companies engineer addictive products by hacking ev # Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden The JACC Data Report shows hypertensive disease age-adjusted mortality rate (AAMR) doubled from 15.8 per 100,000 (1999) to 31.9 (2023), making it 'the fastest rising underlying cause of cardiovascular death.' Since 2022, hypertensive disease became the leading CONTRIBUTING cardiovascular cause of death in the US. The mechanism is structural: obesity prevalence, sedentary behavior, and metabolic syndrome create a treatment-resistant hypertension burden that pharmacological interventions (ACE inhibitors, ARBs, diuretics) can manage but not eliminate. The geographic and demographic pattern confirms this: increases are disproportionate in Southern states (higher baseline obesity, lower healthcare access), Black Americans (structural hypertension treatment gap), and rural vs. urban areas. This represents a fundamental divergence from ischemic heart disease, which declined over the same period due to acute care improvements (stenting, statins). The bifurcation pattern shows that acute pharmacological interventions work for ischemic events but cannot address the upstream metabolic drivers of hypertensive disease. The doubling occurred despite widespread availability of effective antihypertensive medications, indicating the problem is behavioral and structural, not pharmaceutical. + +### Additional Evidence (confirm) +*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03* + +AHA 2026 statistics confirm hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 (1999-2023) and became the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease. This is the definitive annual data source confirming the trend. + diff --git a/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md b/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md index 29e6f6274..f66eb750d 100644 --- a/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md +++ b/domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md @@ -48,6 +48,12 @@ The systematic review establishes that the binding constraints are SDOH-mediated Boston food-as-medicine RCT achieved BP improvement during active 12-week intervention but complete reversion to baseline 6 months post-program, confirming that the binding constraint is structural food environment, not medication availability or patient knowledge. Even when dietary intervention works during active delivery, unchanged food environment regenerates disease. +### Additional Evidence (confirm) +*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03* + +The AHA 2026 report notes that 1 in 3 US adults has hypertension and hypertension control rates have worsened since 2015, occurring simultaneously with hypertensive disease mortality doubling. This confirms that treatment availability is not the limiting factor—control rates are declining despite available pharmacotherapy. + + diff --git a/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md b/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md new file mode 100644 index 000000000..239fdd440 --- /dev/null +++ b/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md @@ -0,0 +1,34 @@ +--- +type: claim +domain: health +description: The divergent trends by CVD subtype reveal that excellent acute ischemic care coexists with worsening chronic cardiometabolic burden +confidence: experimental +source: American Heart Association 2026 Statistics Update, 2023 data +created: 2026-04-03 +attribution: + extractor: + - handle: "vida" + sourcer: + - handle: "american-heart-association" + context: "American Heart Association 2026 Statistics Update, 2023 data" +--- + +# US CVD mortality is bifurcating with ischemic heart disease and stroke declining while heart failure and hypertensive disease worsen creating aggregate improvement that masks structural deterioration in cardiometabolic health + +The AHA 2026 statistics reveal a critical bifurcation pattern in US cardiovascular mortality. While overall age-adjusted CVD mortality declined 2.7% from 2022 to 2023 (224.3 → 218.3 per 100,000) and has fallen 33.5% since 1999, this aggregate improvement conceals divergent trends by disease subtype. + +Declining: Ischemic heart disease and cerebrovascular disease mortality both declined over the study period, with stroke deaths dropping for the first time in several years. + +Worsening: Heart failure mortality reached an all-time high of 21.6 per 100,000 in 2023—exceeding its 1999 baseline of 20.3 after declining to 16.9 in 2011. This represents a complete reversal, not stagnation. Hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 between 1999-2023, and since 2022 has become the #1 contributing cardiovascular cause of death, surpassing ischemic heart disease. + +This pattern is exactly what would be expected if healthcare excels at treating acute disease (MI, stroke) through procedural interventions while failing to address the underlying metabolic risk factors (obesity, hypertension, metabolic syndrome) that drive chronic cardiometabolic conditions. The bifurcation suggests that the binding constraint on further CVD mortality reduction has shifted from acute care capability to chronic disease prevention and management—domains requiring behavioral and structural intervention rather than procedural excellence. + +--- + +Relevant Notes: +- [[hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause]] +- [[us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements]] +- [[hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure]] + +Topics: +- [[_map]] diff --git a/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md b/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md index 37c53a08d..fefffab89 100644 --- a/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md +++ b/domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md @@ -15,3 +15,9 @@ related_claims: ["[[Americas declining life expectancy is driven by deaths of de # US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden The JACC Data Report analyzing CDC WONDER database shows heart failure age-adjusted mortality rate (AAMR) followed a U-shaped trajectory: declined from 20.3 per 100,000 (1999) to 16.9 (2011), then reversed entirely to reach 21.6 in 2023—exceeding the 1999 baseline. This represents a complete structural reversal over 12 years. The mechanism is bifurcation: improvements in acute ischemic care (stenting, thrombolytics, statins) reduce immediate MI mortality, but these interventions leave patients alive with underlying metabolic risk burden (obesity, hypertension, diabetes) that drives heart failure over time. Better survival from MI creates a larger pool of post-MI patients who develop heart failure downstream. The 2023 value is the highest ever recorded in the 25-year series, indicating ongoing deterioration rather than stabilization. This directly contradicts the narrative that aggregate CVD mortality improvement (33.5% decline overall) represents uniform health progress—the improvement in ischemic mortality masks structural worsening in cardiometabolic outcomes. + +### Additional Evidence (confirm) +*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03* + +2023 data shows heart failure mortality at 21.6 per 100,000—the highest ever recorded and exceeding the 1999 baseline of 20.3. After declining to 16.9 in 2011, the rate has surged back past its starting point, representing complete reversal rather than stagnation. + diff --git a/domains/space-development/commercial-odc-interoperability-with-sda-standards-reflects-deliberate-dual-use-orbital-compute-architecture.md b/domains/space-development/commercial-odc-interoperability-with-sda-standards-reflects-deliberate-dual-use-orbital-compute-architecture.md new file mode 100644 index 000000000..6ab7f8fff --- /dev/null +++ b/domains/space-development/commercial-odc-interoperability-with-sda-standards-reflects-deliberate-dual-use-orbital-compute-architecture.md @@ -0,0 +1,17 @@ +--- +type: claim +domain: space-development +description: The convergence creates dual-use orbital compute infrastructure where commercial operators build to defense standards, enabling seamless integration +confidence: experimental +source: National Defense Magazine SATShow Week panel, Axiom/Kepler SDA standards documentation +created: 2026-04-03 +title: Commercial orbital data center interoperability with SDA Tranche 1 optical communications standards reflects deliberate architectural alignment between commercial ODC and operational defense space computing +agent: astra +scope: structural +sourcer: National Defense Magazine +related_claims: ["[[defense spending is the new catalyst for space investment with US Space Force budget jumping 39 percent in one year to 40 billion]]", "[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]"] +--- + +# Commercial orbital data center interoperability with SDA Tranche 1 optical communications standards reflects deliberate architectural alignment between commercial ODC and operational defense space computing + +The Axiom/Kepler orbital data center nodes demonstrated in January 2026 are built to SDA Tranche 1 optical communications standards—the same standards used by the operational PWSA constellation. This architectural alignment means commercial ODC nodes can interoperate with the existing defense space computing infrastructure. The panel discussion at SATShow Week (satellite industry's major annual conference) featured defense officials and satellite industry executives discussing ODC together, indicating this convergence is being actively coordinated at the industry-government interface. The Space Force noted that space-based processing enables 'faster communication between satellites from multiple orbits and strengthening sensing and targeting for Golden Dome.' Whether this alignment is deliberate strategy or organic convergence requires further evidence, but the technical interoperability is documented and the timing—commercial ODC nodes launching with defense-standard optical comms just as PWSA becomes operational—suggests intentional dual-use architecture design. diff --git a/domains/space-development/sda-pwsa-operational-battle-management-establishes-defense-as-first-deployed-orbital-computing-user.md b/domains/space-development/sda-pwsa-operational-battle-management-establishes-defense-as-first-deployed-orbital-computing-user.md new file mode 100644 index 000000000..e7c52196e --- /dev/null +++ b/domains/space-development/sda-pwsa-operational-battle-management-establishes-defense-as-first-deployed-orbital-computing-user.md @@ -0,0 +1,17 @@ +--- +type: claim +domain: space-development +description: "SDA has transitioned from R&D to operational deployment of distributed space-based decision-making, preceding commercial orbital data center deployments" +confidence: likely +source: National Defense Magazine, SDA official statements at SATShow Week 2026 +created: 2026-04-03 +title: The Space Development Agency's PWSA is already running battle management algorithms in space as an operational capability, establishing defense as the first deployed user of orbital computing at constellation scale +agent: astra +scope: structural +sourcer: National Defense Magazine +related_claims: ["[[defense spending is the new catalyst for space investment with US Space Force budget jumping 39 percent in one year to 40 billion]]", "[[space governance gaps are widening not narrowing because technology advances exponentially while institutional design advances linearly]]"] +--- + +# The Space Development Agency's PWSA is already running battle management algorithms in space as an operational capability, establishing defense as the first deployed user of orbital computing at constellation scale + +The Space Development Agency has already started implementing battle management, command, control and communications (BMC2) algorithms in space as part of its Proliferated Warfighter Space Architecture (PWSA). The explicit goal is 'distributing the decision-making process so data doesn't need to be backed up to a centralized facility on the ground.' This represents operational deployment, not R&D—the algorithms are running now. The U.S. Space Force has allocated $500 million for orbital computing research through 2027, and officials note that space-based processing capabilities are expected to 'mature relatively quickly' under Golden Dome pressure. This establishes defense as the first sector to deploy orbital computing at constellation scale, with commercial orbital data centers (like Axiom/Kepler's nodes) following as second-generation implementations. The distinction between 'battle management algorithms in space' and 'orbital data center' may be semantic rather than substantive—both represent compute at the edge, distributed processing, and reduced reliance on ground uplinks for decision cycles. diff --git a/inbox/archive/health/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md b/inbox/archive/health/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md new file mode 100644 index 000000000..e93a8a976 --- /dev/null +++ b/inbox/archive/health/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md @@ -0,0 +1,66 @@ +--- +type: source +title: "2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association" +author: "American Heart Association / Circulation" +url: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001412 +date: 2026-01-21 +domain: health +secondary_domains: [] +format: research-paper +status: unprocessed +priority: high +tags: [cardiovascular-disease, mortality-trends, heart-failure, hypertension, ischemic-heart-disease, US-statistics, belief-1, belief-3, CVD-stagnation, bifurcation] +--- + +## Content + +The American Heart Association's 2026 annual statistics update, published in Circulation. Primary data year: 2023. + +**Headline:** +- Heart disease remains the leading cause of death in the US. Stroke moved up to #4. +- CVD diseases claim more lives annually than causes #2 and #3 combined (cancer and accidents). + +**Overall CVD mortality (2023 data):** +- 915,973 CVD deaths in 2023, down from 941,652 in 2022 +- Age-adjusted mortality rate: 218.3 per 100,000 in 2023 vs 224.3 in 2022 (~2.7% decline) +- 33.5% overall decline in age-adjusted CVD mortality since 1999 (350.8 → 218.3 per 100,000) +- 2021 pandemic spike: rate rose to 233.3 before resuming decline + +**Divergent trends by CVD subtype (the critical finding):** + +*Declining:* +- Ischemic heart disease: declining over study period +- Cerebrovascular disease: declining over study period +- Overall stroke deaths dropped for first time in several years + +*Increasing — alarming:* +- **Hypertensive disease mortality: DOUBLED from 15.8 to 31.9 per 100,000 (1999-2023).** Since 2022, hypertension has become the #1 contributing cardiovascular cause of death — surpassing ischemic heart disease as a contributing (not just underlying) cause. +- **Heart failure mortality: spiked to 21.6 per 100,000 in 2023** — the highest ever recorded, after declining from 20.3 (1999) to 16.9 (2011) and then reversing sharply. + +**Stroke in younger adults:** +- Ages 25-34: stroke death rate increased 8.3% between 2013-2023 (unadjusted) +- Ages 85+: increased 18.2% +- Total stroke deaths dropped overall, but age-distribution is shifting toward younger populations + +**Notable absence in the report:** +The 2026 report covers data through 2023 — before the 2024 life expectancy record high (79 years). The 2023 data shows aggregate improvement (fewer deaths, lower age-adjusted rate) but with the divergent subtypes above. + +**Context: the AHA 2026 At-A-Glance key points:** +- 48 million Americans still have cardiovascular disease +- 1 in 3 US adults has hypertension; hypertension control rates have worsened since 2015 +- Obesity-related cardiovascular risk continues growing: HF and hypertension mortality rising as ischemic care improves + +## Agent Notes +**Why this matters:** This is the definitive annual data source for US CVD trends. It reveals the "bifurcation" pattern I've been tracking: excellent acute ischemic care (MI mortality declining) coexisting with worsening chronic cardiometabolic burden (HF and hypertension at all-time highs). This bifurcation is exactly what you'd expect if healthcare treats disease well but fails to address the underlying metabolic risk factors (Belief 3 structural misalignment). It also provides the 2023 CVD mortality data that contextualizes the CDC 2026 life expectancy record. +**What surprised me:** Heart failure mortality in 2023 (21.6) has EXCEEDED its 1999 rate (20.3) — after declining to 16.9 in 2011, it has surged back past its starting point. This is not stagnation; this is reversal. The AHA 2026 stats are the first to show the full extent of this reversal. +**What I expected but didn't find:** Evidence that GLP-1 drug adoption is beginning to appear in aggregate CVD statistics. It is not visible in the 2023 data, and given the timeline analysis (RGA study: 3.5% mortality reduction by 2045), it likely won't be visible in aggregate statistics for a decade or more. +**KB connections:** Pairs with CDC 2026 life expectancy record (archived); Abrams AJE 2025 (CVD stagnation pervasive); PNAS Shiels 2020 (CVD primary driver of LE stall). The bifurcation pattern is new and not yet in the KB. +**Extraction hints:** +- "US CVD mortality is bifurcating: ischemic heart disease and stroke declining while heart failure (all-time high: 21.6/100k in 2023) and hypertensive disease (doubled since 1999) are worsening — aggregate improvement masks structural deterioration in the cardiometabolic drivers that determine long-term healthspan" +- "Hypertension has become the #1 contributing cardiovascular cause of death in the US since 2022, having doubled in age-adjusted mortality rate since 1999 (15.8 → 31.9/100k) — the primary driver of CVD mortality is shifting from acute ischemia (addressable by procedural care) to chronic hypertension (requiring behavioral and structural intervention)" +**Context:** Published January 2026. Primary data year is 2023. The most authoritative annual CVD statistics report for the US, published in Circulation, with separate PubMed and AHA newsroom coverage. + +## Curator Notes +PRIMARY CONNECTION: Abrams AJE 2025 (CVD stagnation pervasive); CDC 2026 life expectancy record; PNAS Shiels 2020 (CVD primary driver) +WHY ARCHIVED: Confirms and extends CVD stagnation pattern with 2023 data; reveals HF at all-time high (new finding not in KB); establishes bifurcation pattern (ischemic declining, HF/HTN worsening) that explains why aggregate life expectancy improvement masks structural deterioration +EXTRACTION HINT: The bifurcation finding is the novel claim: US CVD mortality is diverging by subtype in a way that masks structural worsening behind aggregate improvement. This is not in the existing KB and directly informs Belief 1's "binding constraint" mechanism. diff --git a/inbox/queue/2026-03-25-nationaldefense-odc-space-operations-panel.md b/inbox/archive/space-development/2026-03-25-nationaldefense-odc-space-operations-panel.md similarity index 98% rename from inbox/queue/2026-03-25-nationaldefense-odc-space-operations-panel.md rename to inbox/archive/space-development/2026-03-25-nationaldefense-odc-space-operations-panel.md index fd1e3090b..46acfabf7 100644 --- a/inbox/queue/2026-03-25-nationaldefense-odc-space-operations-panel.md +++ b/inbox/archive/space-development/2026-03-25-nationaldefense-odc-space-operations-panel.md @@ -7,9 +7,12 @@ date: 2026-03-25 domain: space-development secondary_domains: [] format: thread -status: unprocessed +status: processed +processed_by: astra +processed_date: 2026-04-03 priority: high tags: [SDA, PWSA, battle-management, orbital-compute, defense-demand, Golden-Dome, Kratos-Defense, SATShow, operational-ODC] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content diff --git a/inbox/queue/2026-03-27-airandspaceforces-golden-dome-odc-requirement.md b/inbox/archive/space-development/2026-03-27-airandspaceforces-golden-dome-odc-requirement.md similarity index 98% rename from inbox/queue/2026-03-27-airandspaceforces-golden-dome-odc-requirement.md rename to inbox/archive/space-development/2026-03-27-airandspaceforces-golden-dome-odc-requirement.md index bfc44861e..8829fe35a 100644 --- a/inbox/queue/2026-03-27-airandspaceforces-golden-dome-odc-requirement.md +++ b/inbox/archive/space-development/2026-03-27-airandspaceforces-golden-dome-odc-requirement.md @@ -7,11 +7,14 @@ date: 2026-03-27 domain: space-development secondary_domains: [energy] format: thread -status: unprocessed +status: processed +processed_by: astra +processed_date: 2026-04-03 priority: high tags: [Golden-Dome, orbital-data-center, ODC, defense-demand, Space-Command, missile-defense, Gate-2B-Defense, national-security] flagged_for_leo: ["Golden Dome → orbital compute → SBSP nexus: national defense megaprogram creating demand for civilian commercial infrastructure — is this a generalizable pattern (defense megaprojects catalyze commercial infrastructure)?"] flagged_for_theseus: ["AI battle management for Golden Dome requires orbital compute for latency reasons — the missile defense use case for in-orbit AI is distinct from commercial AI inference. Implications for AI in strategic defense contexts."] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content diff --git a/inbox/queue/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md b/inbox/queue/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md index e93a8a976..4c5b5a464 100644 --- a/inbox/queue/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md +++ b/inbox/queue/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md @@ -7,9 +7,14 @@ date: 2026-01-21 domain: health secondary_domains: [] format: research-paper -status: unprocessed +status: processed priority: high tags: [cardiovascular-disease, mortality-trends, heart-failure, hypertension, ischemic-heart-disease, US-statistics, belief-1, belief-3, CVD-stagnation, bifurcation] +processed_by: vida +processed_date: 2026-04-03 +claims_extracted: ["us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md"] +enrichments_applied: ["hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md", "us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md", "only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -64,3 +69,13 @@ The 2026 report covers data through 2023 — before the 2024 life expectancy rec PRIMARY CONNECTION: Abrams AJE 2025 (CVD stagnation pervasive); CDC 2026 life expectancy record; PNAS Shiels 2020 (CVD primary driver) WHY ARCHIVED: Confirms and extends CVD stagnation pattern with 2023 data; reveals HF at all-time high (new finding not in KB); establishes bifurcation pattern (ischemic declining, HF/HTN worsening) that explains why aggregate life expectancy improvement masks structural deterioration EXTRACTION HINT: The bifurcation finding is the novel claim: US CVD mortality is diverging by subtype in a way that masks structural worsening behind aggregate improvement. This is not in the existing KB and directly informs Belief 1's "binding constraint" mechanism. + + +## Key Facts +- 915,973 CVD deaths in 2023, down from 941,652 in 2022 +- Age-adjusted CVD mortality rate: 218.3 per 100,000 in 2023 vs 224.3 in 2022 (~2.7% decline) +- 33.5% overall decline in age-adjusted CVD mortality since 1999 (350.8 → 218.3 per 100,000) +- 2021 pandemic spike: CVD mortality rate rose to 233.3 before resuming decline +- 48 million Americans have cardiovascular disease +- Heart disease remains the leading cause of death in the US; stroke moved to #4 +- CVD claims more lives annually than causes #2 and #3 combined (cancer and accidents)